Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ